Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 2108-2113, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cattozzo, G.
Right arrow Articles by Melzi d’Eril, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cattozzo, G.
Right arrow Articles by Melzi d’Eril, G.
Related Collections
Right arrow Laboratory Management
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2001;47:2108-2113.)
© 2001 American Association for Clinical Chemistry, Inc.

Articles

Commutability of Calibration and Control Materials for Serum Lipase

Giampaolo Cattozzo1a, Carlo Franzini2 and Gianvico Melzi d’Eril1,3

1 Ospedale F. Del Ponte-A. O. Fondazione Macchi, 21100 Varese, Italy.

2 Universitèa di Milano, 20157 Milano, Italy.

3 Universitèa dell’Insubria, 21100 Varese, Italy.

aAddress correspondence to this author at: Laboratorio di Analisi, Ospedale F. Del Ponte-A. O. Fondazione Macchi, Via F. Del Ponte, 19, 21100 Varese, Italy. Fax 39-0332-299408; e-mail giampaolo.cattozzo{at}tin.it.

Background: To effectively assess and correct for intermethod variability, calibration and control materials (CCMs) must show the same intermethod behavior as patient sera, i.e., they must be commutable. We describe the commutability of selected CCMs for lipase assays, the impact of noncommutability of CCMs in normalizing patient results, and characteristics of reagents that affect assay specificity and commutability.

Methods: Lipase was measured in 98 patient sera and in 29 commercial CCMs, with 2 commercial methods using different substrates and with 4 experimental methods using 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6'-methylresorufin) ester as substrate and colipase as cofactor, but differing in the stabilizing proteins used and in the size of the substrate micelles.

Results: The noncommutability rate, i.e., the frequency of aberrant intermethod behavior of CCMs in comparison with patient sera, was 27% for liquid CCMs and 47% for lyophilized CCMs. The normalized residuals, measuring the degree of noncommutability, were -2.3 to 2.4 for CCMs with "normal" lipase activity, and -3.5 to 21.7 for CCMs with higher lipase activity. Recalculation of patient results with CCMs as calibrators decreased or increased the original bias according to whether the CCMs were commutable.

Conclusions: For the lipase methods in this study, the frequency of noncommutability of CCMs is affected by assay-specific characteristics, including size of substrate micelles and the presence or absence of added proteins.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.